Press releases
- Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
- Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
- Ironwood Pharmaceuticals Reports First Quarter 2024 Results
- Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
- Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
- Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
- Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
More ▼
Key statistics
As of last trade Ironwood Pharmaceuticals Inc (I76:MUN) traded at 5.95, 9.17% above its 52-week low of 5.45, set on May 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.95 |
---|---|
High | 5.95 |
Low | 5.95 |
Bid | 5.80 |
Offer | 5.95 |
Previous close | 5.95 |
Average volume | 0.71 |
---|---|
Shares outstanding | 158.96m |
Free float | 156.35m |
P/E (TTM) | -- |
Market cap | 1.02bn USD |
EPS (TTM) | -6.79 USD |
Data delayed at least 15 minutes, as of Jun 10 2024 07:16 BST.
More ▼